Kornimate/medical-research-clean huggingface dataset:
study to assess safety and tolerability of multiple doses of eo2002

Conditions: Corneal Edema; Corneal Endothelial Dystrophy; Endothelial Dysfunction; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy; Bullous Keratopathy; Pseudophakic Bullous Keratopathy; Corneal Edema Pseudophakic

Summary: the goal of this clinical study is to assess the safety of multiple intracameral injections of eo2002 with and without topical ripasudil.


Eligibility criteria:
inclusion criteria: all ocular criteria apply to the study eye unless otherwise noted. 1. age ≥ 18 years. 2. subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus). 3. symptomatic corneal edema associated with endothelial dysfunction which may be secondary to fuchs' corneal dystrophy or pseudophakic bullous keratopathy. key exclusion criteria: all ocular criteria apply to the study eye unless otherwise noted. 1. other corneal disease 2. anterior chamber intraocular lens 3. sutured or scleral-fixated intraocular lens. 4. macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in bcva. 5. history of refractive surgery. 6. history of vitrectomy 7. descemet membrane detachment. 8. history of uveitis or other ocular inflammatory disease. 9. history of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant). 10. iop \>21 or \<7 mm hg 11. prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty. 11. history of ocular neoplasm. 12. etdrs bcva in the fellow eye is worse than 35 letters (snellen equivalent of 20/200). 13. female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study. 14. subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration. 15. any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.
efficiency of modified pilates exercises in patients with chronic neck pain

Conditions: Neck Pain

Summary: the aim of this study is to investigate the effects of modified pilates exercises on neck pain, deep neck flexor muscles edurance, joint position sense and functionality in patients with chronic neck pain.

50 individuals with chronic neck pain not working will be included to our study. we will evaluate pain (with visual analog scale), deep neck flexors' endurance (with cranio-cervical flexure test using the pressure stabilizing feedback device), cervical range of motion and cervical proprioception (wit cervical range of motion device). besides we will conduct a questionnaire (neck disability index) to get further knowledge about their functionality. participants will be randomly allocated 2 groups consisting of 25 participants and these 2 groups will receive different interventions. modified pilates exercise group (mpeg) will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week in the presence of a physiotherapist. the control group (kg) will receive daily routine advises to prevent neck pain and they will be asked about to apply these advises and not to make other changes in their life. the evaluations will be repeated and analyzed 2 times, pre-treatment and 6 weeks after treatment , and the effectiveness of the modified pilates exercises will be examined in the chronic neck pain. our hypothesis is ''modified pilates exercises have a positive effect on neck pain, range of motion, deep neck flexor muscles, joint position sense and function in patients with chronic neck pain.''

Eligibility criteria:
inclusion criteria: * having neck pain more than 3 months * no physical therapy in last year * no background with pilates exercises * being able to understand turkish, treatment and evaluations. * being able to complete all the evaluations and treatment exclusion criteria: * fracture or surgery background with shoulder, cervical area or other extremities. * any systemic musculoskeletal diseases * existing chest deformities or scoliosis * cervical hernia, neuropathy or whiplash. * pregnancy * having pain above 7 in vas * any other pain that could prevent people from doing exercises

Keywords: exercise pilates modified pilates chronic neck pain
deep brain stimulation (dbs) of the globus pallidus (gp) in huntington's disease (hd)

Conditions: Huntington Disease

Summary: the aim of the study is to prove the efficacy and safety of pallidal dbs in hd patients and to show superiority of dbs on motor function in the stimulation group compared to stimulation-off group

in this study the efficacy and safety of pallidal deep brain stimulation (dbs) in hd patients shall be investigated and superiority of dbs on motor function in the stimulation group compared to the stimulation-off group shall be shown. this study is a prospective, randomised, double blind, parallel group, sham-controlled, multi-centre trial. patients in the stimulation group will be stimulated for three months while the stimulator in the sham-group will be turned off for three months. after three months the primary endpoint will be assessed. afterwards the stimulator will be turned on in all patients.

Eligibility criteria:
inclusion criteria: * clinically symptomatic and genetically confirmed hd (number of cag repeats ≥ 36) * age ≥18 years * moderate stage of the disease (uhdrs motor score ≥ 30) * chorea despite best medical treatment (uhdrs chorea subscore ≥ 10) * mattis dementia rating scale ≥ 120 (or \> 80% of items testable independently from motor impairment) * patient has stable medication prior six weeks before inclusion * signed informed consent exclusion criteria: * juvenile hd (westphal variant) or predominant bradykinesia * postural instability with uhdrs retropulsion score \> 2 * severe comorbidity compromising operability and/or life expectancy and/or quality of life during the trial duration (e.g. cancer with life expectancy \< 6 months, nyha 3 and 4 rising the anaesthetic risk according to the anaesthesiologist) * acute suicidality * acute psychosis (symptoms within previous 6 months) * participation in any interventional clinical trial within 2 months before screening * cortical atrophy grade 3 * patients with risk of coagulopathies and/or increased risk of haemorrhage * patients with an implanted pacemaker or defibrillator * pregnancy * lactation

Keywords: huntington disease dbs chorea
long-term follow-up of adult with atorpphic scars treated with trtp-101

Conditions: Atrophic Scar

Summary: cic101-01-lt is a long-term follow-up study of subjects treated with trtp-101 and will evaluate the long-term safety and efficacy of trtp-101.

the long-term safety of trtp-101 was evaluated by participants in the cic101-01 clinical trial and followed up for 5 years for serious adverse events.

Eligibility criteria:
inclusion criteria: * received trtp-101 in clinical trial cic101-01 * provided written informed consent to participate in this study exclusion criteria: * judged to be unsuitable to participate in this long-term follow-up
omar opioid use disorder

Conditions: Healthy Control; Opioid Use Disorder

Summary: the goal of this research study is to examine the endocannabinoid (ecb) function in vivo in individuals with opioid use disorder (oud) by measuring cannabinoid receptor 1 (cb1r) availability.

the investigators will image brain cannabinoid receptors using positron emission tomography (pet) imaging and the radioligand \[11c\] omar, in healthy individuals and individuals diagnosed with opioid use disorder. research participants may complete screening, mri, pet scan and follow up visits.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * male and female 18 years and older * dsm-5 diagnosis of opioid use disorder (for oud group) * physically healthy i.e., no clinically unstable medical conditions * written informed consent and have capacity to consent and comply with study procedures exclusion criteria: * current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the oud group). * presence of ferromagnetic metal in the body or heart pacemaker * have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits * are claustrophobic
comparison of stenting versus best medical therapy for treatment of ostial renal artery stenosis: a trial in patients with advanced atherosclerosis

Conditions: Renal Artery Stenosis

Summary: renal artery stenosis (ras) usually refers to a disease of the large extra-renal arterial vessels and most frequently is caused by atherosclerotic obstructions. the prevalence of atherosclerotic ras increases with age, male gender, traditional cardiovascular risk factors (hypertension, diabetes, smoking, hyperlipidemia) and atherosclerotic comorbidities like coronary artery or peripheral artery disease (pad). a prevalence up to 40% has been reported in patients with pad. undoubtedly, atherosclerotic ras is a progressive disease, as more than half of the patients exhibit an increasing degree of stenosis within five years after diagnosis, and one out of five patients with a critical stenosis (\>60%) suffers renal atrophy and renal failure during this period. ras may be treated conservatively by so called best medical treatment, surgically, or by endovascular interventions using balloon angioplasty and stenting. the purpose of the investigators study is to determine the incidence and the predictors of ras in patients with pad, and to compare the effect of renal artery stenting versus best medical treatment in patients with hypertension and ostial renal artery stenosis in a randomized controlled trial.


Eligibility criteria:
inclusion criteria: * pad and unilateral ostial \>60% ras and hypertension exclusion criteria: * conditions which imply ras stenting (bilateral significant renal disease, single functioning kidney, or patients whose conditions cannot be managed medically or by intervention) * allergy to contrast agents or medication administered for best medical treatment (in particular asa and statins)

Keywords: renal artery stenosis stent comparison of treatments progression atherosclerosis peripheral artery disease major cardiovascular events
exploratory study of a novel based rbcdna liquid biopsy technique for colorectal cancer early detection

Conditions: Colorectal Cancer; Adenomatous Polyps; Adenoma; Advanced Adenoma

Summary: exploration of a novel rbcdna liquid biopsy technique for early detection of colorectal cancer is a promising development in the field of disease diagnosis and screening. this technique has the potential to establish an efficient and sensitive system for the early detection of colorectal cancer, which can provide a new perspective for individual health monitoring.

patients who are at high risk of developing colorectal cancer and willing to undergo colonoscopy examination will be asked to collect a stool sample prior to bowel preparation for commercially available fit (fecal immunochemical test) assay, as well as a blood sample for rbcdna testing. the colonoscopy and histopathologic examination will be used as a reference for the results obtained from these tests.

Eligibility criteria:
inclusion criteria: 1. age:40-74years 2. sex:all 3. willing to provide written consent 4. plan to undergo colorectaloscopy or surgical treatment and be able to provide a complete medical history and cooperate with blood sampling and follow-up visits，other operation. for advanced adenomas (aa) group: 1. adenomatous polyps with ≥25% villous component, high-grade dysplasia (hgd), or a diameter ≥10 mm were considered aa. sessile serrated lesions with diameters ≥10 mm. 2. treatment-naive 3. no other comorbid tumors for crc group: 1. confirmed crc patients 2. treatment-naive 3. no other comorbid tumors exclusion criteria: 1. patients with colorectal cancer who have received prior treatment. 2. fap (familial adenomatous polyposis), crohn's disease, ulcerative colitis 3. participants taking anticoagulants such as aspirin or warfarin, or those with coagulation disorders. 4. prior history of colonoscopy within the past 5 years and removal of lesions 5. pregnancy or intestinal infarction people 6. unable to provide informed consent 7. participants in other clinical trials or who have participated in other clinical trials within 60 days. 8. unable to provide stool sample and follow-up visits. 9. presence of major infectious diseases (e.g. hiv, etc.)
hemodynamic effects of terlipressin and high dose octreotide

Conditions: Gastric and Esophageal Varices

Summary: the purpose of the study is to find patients's response to terlipressin and octreotide during hepatic venous pressure gradient measurement by observing portal and systemic hemodynamics.

esophageal variceal bleeding is one of the main causes of death in cirrhosis patients. prevention of bleeding events, including primary and secondary prophylaxis, is very important for reducing the mortality of variceal bleeding. terlipressin and octreotide can effectively control bleeding with few side effects, which has been recommended by baveno v in treatment of acute variceal bleeding. terlipressin and high dose octreotide will be administered to the patients with cirrhosis related esophageal varices when they undergo hepatic venous pressure gradient measurement. changes from portal and systemic hemodynamics will be observed to evaluate the safety and effects of terlipressin and high dose octreotide as well as to determine wether patients respond to them. the results can be served as clinical evidence for preventing re-bleeding through long-acting terlipressin and octreotide in the future.

Eligibility criteria:
inclusion criteria: * gastric and esophageal varices have been confirmed through endoscopy * liver biopsy, ct or mri indicates cirrhosis * patients who experienced variceal bleeding exclusion criteria: * the patients who are beyond the range from 18 to 80 years old * the patients with unstable vital signs * the patients with spontaneous peritonitis or other severe infections * the patients with hepatorenal syndrome or renal inadequacy * the patients with uncontrolled hepatic encephalopathy * pregnant and lactating women * the patients who had contraindications for terlipressin or octreotide * the patients who refuse to take part in this study

Keywords: gastric and esophageal varices hepatic venous pressure gradient terlipressin octreotide
specific oral tolerance induction to cow's milk allergy

Conditions: Food Hypersensitivity

Summary: background: limited published evidence shows specific oral tolerance induction (soti) to be a potential intervention option for cow's milk proteins (cmps) allergy. our hypothesis is that soti should be started early in order to improve its efficacy and prevent cmps sensitization from evolving towards persistent allergy. the aim of this study was to evaluate the safety and efficacy of soti in 2-year-old children with cow's milk allergy, as a treatment alternative to elimination diet. methods: a total of 60 children between 24-36 months of age with ige-mediated allergy to cmps were included in this multicenter study and were randomly divided into two different groups. thirty children (group a: treatment group) began soti immediately, whereas the remaining 30 (group b: control group) were kept on a milk-free diet and followed-up on for one year.


Eligibility criteria:
inclusion criteria: 1. -infants between 24-36 months of age. 2. -ige-mediated allergy to cmps meeting all the following diagnostic criteria: * immediate-type clinical manifestations, skin (urticaria, angioedema and/or erythema), digestive (acute vomiting and/or diarrhea) or respiratory (bronchospasm and/or rhinitis) involvement in the first two hours after cow's milk ingestion. * skin test readings ≥ 3 mm and specific ige titers \> 0.35 ku/l for whole cow's milk or someone of isolated cmps (casein, alpha-lactalbumin, beta-lactoglobulin ) 3. -persistence of cmp allergy in the four weeks prior to tolerance induction, based on the following criteria: * skin (prick) test readings ≥3 mm and specific ige titers (cap-feia) \>0.35 ku/l for whole cow's milk or someone of isolated cmps (casein, alpha-lactalbumin, beta-lactoglobulin ) * double-blind placebo-controlled challenge (dbpcfc) positive to cow's milk. 4. -written informed consent from the parents. exclusion criteria: 1. -clinical manifestations of anaphylactic shock after the ingestion of cow's milk. 2. -non-ige-mediated or non-immunological adverse reactions to cow's milk. 3. -malignant or immunopathological diseases and/or severe primary or secondary immune deficiencies. 4. -patients receiving immunosuppressor therapy. 5. -patients receiving beta-blockers (including topical formulations). 6. -associated diseases contraindicating the use of adrenalin: cardiovascular disease or severe hypertension

Keywords: cow's milk allergy food allergy oral desensitization randomized trial specific oral tolerance induction.
study of kw-0761 in subjects with ccr4-positive peripheral t/nk-cell lymphoma

Conditions: Peripheral T/NK-cell Lymphoma

Summary: the purpose of this study is to evaluate the efficacy of kw-0761 intravenously administered eight times at one-week intervals in patients with ccr4-positive peripheral t/nk-cell lymphoma. the primary objective is to assess the antitumor effect in terms of best overall response, while the secondary objectives are to assess the antitumor effect in terms of best response by disease lesion, to assess the progression-free survival and to assess the overall survival. the safety and pharmacokinetic profiles of kw-0761 will be also evaluated.


Eligibility criteria:
inclusion criteria: * subjects with hematologically or pathohistologically diagnosed peripheral t/nk-cell lymphoma * subjects who have been positive for ccr4 * subjects who received one or more chemotherapy regimens * subjects who relapse after achieving complete response, uncertain complete response or partial response by the last chemotherapy * subjects who have an interval of 4 weeks or more between the last day of the prior therapy and the scheduled day of the first kw-0761 treatment * subjects with nodal lesions, extranodal lesions and/or cutaneous lesions * subjects who have a performance status of 0 to 2 * subjects who are negative for hbs antigen and reported as "not detected" for hbv-dna * subjects who are negative for anti-hcv antibody * subjects who have normal function of the major organs * subjects who have given written voluntary informed consent to participate in the study exclusion criteria: * subjects who underwent transplant therapy such as hematopoietic stem-cell transplantation (subjects who underwent autologous hematopoietic stem-cell transplantation following chemotherapy will not be excluded) * subjects who are known carriers of hiv * subjects who have active multiple cancer * subjects who have a history of allergic reactions to therapeutic antibodies * subjects requiring continuous systemic treatment with steroid * subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses at enrollment or who may require such radiotherapy after the start of the study * subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children
a study to detect progression of mass effect from unilateral brain lesions

Conditions: Non-traumatic Hemispheric Brain Lesions

Summary: the purpose of this research is to gather information on the safety and effectiveness of the brain4care device for measuring intracranial pressure without invasive procedures.


Eligibility criteria:
inclusion criteria: * adult patients with non-traumatic hemispheric brain lesions deemed at risk for progression of mass effect and possible subfalcine and/or uncal herniation. * patients admitted the neuroscience icu for serial neurological monitoring. * patients whose care is not expected to include immediate surgical decompression. exclusion criteria: * patients under the age of 18. * patients who are unable to provide consent due to neurologic deficit and does not have a surrogate decision maker available to provide consent.
neuromodulation in covid-19 patients

Conditions: COVID-19

Summary: this clinical study is aimed at investigating the effects of transcranial direct current stimulation (tdcs) on covid-19 patients not admitted to the intensive care unit. the tdcs is a non-invasive brain stimulation technique which applies a low intensity electrical current in order to modulate neuronal activity. patients included will be submitted to a single session with active or sham tdcs, aiming to modulate prefrontal or supplementary motor area (sma). evaluation protocol will be performed before and after stimulation to verify the incidence of adverse events related to treatment and whether tdcs would affect measures of executive functioning, mood, anxiety, autonomic response and motor function in covid-19 patients. we hypothesize the neuromodulation would be a safety, promising treatment to reduce possible impairments in covid-19 patients.


Eligibility criteria:
inclusion criteria: * suspected or confirmed diagnosis for sars-cov-2; * ability to understand and execute the proposed protocol; * vital signs (body temperature \<38ºc, blood pressure between 90 x 60mmhg and 140 x 90 mmhg, respiratory rate between 12 e 30 bpm). exclusion criteria: * dyspnea or signs of respiratory effort; * spo2 ≤ 90%; * hemodynamic instability; * deep vein thrombosis, active bleeding, use of cardiac pacemaker; * injury, pain or metallic implants in the cranium or scalp; * seizure history; * suspected or confirmed pregnancy; * concomitant or previous rheumatic or neurological diseases; * severe psychiatric diseases (schizophrenia, bipolar disorder, intellectual disability); * severe musculoskeletal and/or integumentary disorders; * severe psychiatric disorders; * severe liver or kidney disease.

Keywords: sars-cov-2 transcranial direct current stimulation (tdcs) executive function depression anxiety autonomic nervous system motor function
surface roughness of heat cured acrylic resin versus acrylic resin with titanium dioxide

Conditions: Denture Stomatitis

Summary: measurement of surface roughness of tow different material of denture base to find out which material is more hygienic by decreasing the amount of bacterial accumulation.

using a denture base material as a standard value which is the rapid heat cured acrylic resin and compare it with a new material which is a conventional acrylic resin with addition of titanium dioxide nano particles in surface roughness and measuring it by a device called stylus profilometer this will be done on 20 patients this trial will take about 6 months.

Eligibility criteria:
inclusion criteria: 1. completely edentulous maxillary arch and fully dentate mandibular arch with adequate interarch space. 2. the edentulous ridges should be covered by firm healthy mucosa. 3. angle class i maxillomandibular relationship 4. healthy and co-operative patients exclusion criteria: 1. patients with bad habits as severe clenching or bruxism, drug or alcohol addiction, moderate or heavy smoking (greater than 10 cigarettes/day). 2. previous history of radiotherapy or chemotherapy. 3. any skeletal problem dictates surgical intervention